

## Effectiveness of N-[3-Chloro-2-(Substituted)-4-Oxazetidin-1-Yl]-4-(1h-Indol-3-Yl) Butanamide Derivatives as A-Amylase Inhibitors

Neethu Mathew<sup>1,\*</sup>, M. Sukumar<sup>2</sup>, T. K Ravi<sup>3</sup>, Arunkumar R<sup>4</sup>, Betty Carla<sup>5</sup>

<sup>1,2,3,4,5</sup>Department of Pharmaceutical Chemistry, St. Joseph's College of Pharmacy, Cherthala-688524, India.

**\*Corresponding Author:**

E-mail: stjosephdpharm@gmail.com

### ABSTRACT

Various N-[3-Chloro-2-(substituted)-4-oxazetidin-1-yl]-4-(1H-indol-3-yl) butanamide derivatives have been synthesized by the cyclo condensation of Schiff bases with tri ethyl amine and chloro acetyl chloride. The structures of the newly synthesized compounds have been established on the basis of their spectral data. All compounds were evaluated for  $\alpha$ -amylase inhibitory activity. All compounds investigated exhibited significant activity, comparable to that of the standard used.

**Keywords:** N-[3-Chloro-2-(4-hydroxy-3-methoxy phenyl)-4-oxazetidin-1-yl]-4-(1H-indol-3-yl) butanamide,  $\alpha$ -amylase inhibitor.

### INTRODUCTION

Azetidin-2-ones are four membered heterocyclic compounds, commonly known as  $\beta$ -lactam, having a wide variety of physiological functions. The research on azetidin-2-one moiety has done extensively throughout the world as a result of the discovery of the antibacterial properties of penicillins, cephalosporins and cephamycins. N-[3-Chloro-2-(4-hydroxy-3-methoxy phenyl)-4-oxazetidin-1-yl]-4-(1H-indol-3-yl) butanamide derivatives contain  $\beta$ -lactam moiety. Recently, many azetidin-2-one derivatives were reported to have various pharmacological activities such as antimicrobial (Keri *et al.*, 2010), antitubercular, anti-inflammatory, antitumor, anti-HIV, anti parkinsonian, anti-diabetic and vasopressin V1a antagonist (Mehta *et al.*, 2010).

### Experimental

Melting points were taken in open capillaries and are uncorrected. Progress of reactions was monitored by thin layer chromatography using methanol: chloroform (8:2) as mobile phase. The spot was visualized by exposing dry plate in iodine chamber. IR spectra were recorded in KBr disc on a JASCO FT/IR-140 spectrophotometer and <sup>1</sup>HNMR spectra was measured on a Bruker-400 MHz spectrometer. The Mass spectra were recorded on a Shimadzu instrument. The reagent grade chemicals were purchased

from the commercial sources and further purified before use.

### Synthesis of Indole-3-butyric acid ester

A mixture of 20.4 g (0.1 mole) of indole-3-butyric acid, methanol (6.4ml), dichloromethane (100ml) and concentrated sulphuric acid (5 drops) was refluxed for 5 hrs and cooled to 5°C. The contents were poured into ice water (100 ml). The organic layer at the bottom was separated and dichloromethane was distilled off to get the crude product. The high vacuum distillation of this crude product afforded the pure compound which is crystallized from methanol. The purity of the indole-3-butyric acid ester was established by single spot on the TLC plate. The solvent system used was methanol: chloroform (3:1) (Holla *et al.*, 2004; Mohan *et al.*, 2004).

### Synthesis of Indole -3-butyric acid hydrazine

To the indole-3-butyric acid ester (21.7g; 0.1 mole) in ethanol (20 ml), hydrazine hydrate (99% - 2 ml) was added in drops with constant stirring and the mixture was refluxed for 4 hours. After cooling, the solution was poured on to crushed ice. The solid separated was filtered, dried and recrystallized from methanol. The purity of the compound was established by single spot on the TLC plate. The solvent system

used was methanol: chloroform (3:1) (Govindarajan and bhat, 2002).


### Synthesis of Schiff's base

Indole-3-acid hydrazide (0.1 mole) and arylaldehyde (0.1 mole) were dissolved in ethanol (15ml) in a 100 ml beaker and refluxed for 2 hrs. The reaction mixture was cooled and the solid formed was separated by filtration, washed with cold ethanol and recrystallised from ethanol. Purity of the product was established by single spot on the TLC plate. The solvent system used was methanol:chloroform (3:1) (Udupi *et al.*, 2000).

### Synthesis of substituted azetidin-2-ones

A mixture of Schiff base (0.01 moles) in DMF was taken in a 100 ml beaker. To it chloroacetylchloride (0.01 mole; 1.12ml) and trimethylamine (1ml) were added slowly. Then the mixture was placed inside a microwave oven for about 3-4 minutes at a power level of 20%. Finally the mixture was diluted with ice cold water. The solid product obtained was separated by filtration and recrystallized from ethanol. Purity of the product was established by a single spot on the TLC plate. The solvent system used was methanol: chloroform (3:1) (Bhat *et al.*, 2007).

### Scheme



### BIOLOGICAL ACTIVITY


#### $\alpha$ -amylase inhibitory activity

1 ml of 1% w/v soluble starch solution is mixed with 1 ml of test drug solution in a test tube. 1 ml of the test drug solution is taken in different concentrations. To each

tube add 1 ml of enzyme solution and left to react for 3 minutes at 25°C. 1 ml of 3, 5-dinitro salicylic acid is added on each tube. The contents were heated for 10 to 15 minutes on a boiling water bath. The generation of maltose was quantified by the reduction of 3, 5-dinitro salicylic acid to 3-

amino 5-nitro salicylic acid. This reaction (corresponding to color change from orange to red) is measured at 540 nm against the blank. The percentage of inhibition was determined by using the following formula (Volgel HG, 2003).

$$\% \text{ inhibition} = \frac{\text{Control} - \text{test}}{\text{Control}} \times 100$$



**Fig 1: General structure of newly synthesized compounds**

**Table 1: Physical characterization of newly synthesized compounds**

| S. No. | Compound Code | R   | Molecular Formula   | Molecular Weight | Melting Point | % yield | R <sub>f</sub> value |
|--------|---------------|---|---|------------------|---------------|---------|----------------------|
| 1      | AZ1           | 3-OCH <sub>3</sub> -4-OHC <sub>6</sub> H <sub>5</sub> | C <sub>22</sub> H <sub>22</sub> ClN <sub>3</sub> O <sub>4</sub>               | 427.881          | 54            | 72%     | 0.58                 |
| 2      | AZ1           | 3-NO <sub>2</sub> C <sub>6</sub> H <sub>5</sub>       | C <sub>21</sub> H <sub>19</sub> ClN <sub>3</sub> O <sub>4</sub>               | 426.853          | 63            | 78%     | 0.80                 |
| 3.     | AZ3           | 4-Cl C <sub>6</sub> H <sub>5</sub>                    | C <sub>21</sub> H <sub>19</sub> Cl <sub>2</sub> N <sub>3</sub> O <sub>2</sub> | 416.300          | 76            | 88%     | 0.88                 |
| 4.     | AZ4           | 4-OCH <sub>3</sub> C <sub>6</sub> H <sub>5</sub>      | C <sub>22</sub> H <sub>22</sub> ClN <sub>3</sub> O <sub>3</sub>               | 411.881          | 87            | 63%     | 0.65                 |
| 5.     | AZ5           | 4-OHC <sub>6</sub> H <sub>5</sub>                     | C <sub>21</sub> H <sub>20</sub> ClN <sub>3</sub> O <sub>3</sub>               | 397.855          | 78            | 86%     | 0.78                 |

### Characterization of the newly synthesized compounds

The structures of designed and synthesized compounds have been established on the basis of UV, IR, <sup>1</sup>H NMR and Mass spectral data. IR spectra showed the characteristic peaks of newly synthesized compounds. Chemical shifts were reported on δ scale. Mass spectral data confirmed the molecular weight of the synthesized compounds.

#### N-[3-Chloro-2-(4-hydroxy-3-methoxy phenyl)-4-oxazetidin-1-yl]-4-(1H-indol-3-yl)

**butanamide (AZ<sub>1</sub>).** Yield 72%; mp 54°C; R<sub>f</sub> (0.58); λ<sub>max</sub> (295); IR (KBr) ν (cm<sup>-1</sup>); 3367 (Ar-NH); 1595 (C=O); 1718 (β-lactam); 1310 (Sec. Amine); 752 (C-Cl); <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 9.5 (-NH-); 7.0 to 8.0 (Ar-H); 6.8 (β lactam); 3.7 (-OCH<sub>3</sub>).

**N-[3-Chloro-2-(3-nitrophenyl)-4-oxazetidin-1-yl]-4-(1H-indol-3-yl) butanamide (AZ<sub>2</sub>):** Yield 78%; mp 63°C; R<sub>f</sub> (0.80); λ<sub>max</sub> (266); IR (KBr) ν (cm<sup>-1</sup>); 3364 (Ar-NH); 1450 (NO<sub>2</sub>); 1590 (C=O); 1716 (β-lactam); 1305 (Sec. Amine); 749 (C-Cl); <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 9.4 (-NH-); 8.4 (-OH); 7.0 to 8.0 (Ar-H); 6.8 (β lactam).

**N-[3-Chloro-2-(4-Chlorophenyl)-4-oxazetidin-1-yl]-4-(1H-indole-3-yl) butanamide (AZ<sub>3</sub>):** Yield 88%; mp 76°C; R<sub>f</sub> (0.88); λ<sub>max</sub> (285); IR (KBr) ν (cm<sup>-1</sup>); 3372 (Ar-NH); 1592 (C=O); 1728 (β-lactam); 1306 (Sec. Amine); 755 (C-Cl); <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 9.5 (-NH-); 8.3 (-OH); 7.0 to 8.0 (m, 13H, Ar-H); 6.7 (β lactam).

**N-[3-Chloro-2-(4-methoxyphenyl)-4-oxazetidin-1-yl]-4-(1H-indol-3-yl) butanamide (AZ<sub>4</sub>):** Yield 63%; mp 87°C; R<sub>f</sub> (0.65); λ<sub>max</sub> (282); IR (KBr) ν (cm<sup>-1</sup>); 3358 (Ar-NH); 1594 (C=O); 1731 (β-lactam); 1311 (Sec. Amine); 745 (C-Cl); <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 9.4 (-NH-); 8.4 (-OH); 7.0 to 8.0 (Ar-H); 6.8 (β lactam); 3.7 (-OCH<sub>3</sub>).

**N-[3-Chloro-2-(4-hydroxyphenyl)-4-oxazetidin-1-yl]-4-(1H-indol-3-yl) butanamide (AZ<sub>5</sub>):**

Yield 86%; mp 78°C; R<sub>f</sub> (0.78); λ<sub>max</sub> (290); IR (KBr) ν (cm<sup>-1</sup>); 3368 (Ar-NH); 1590 (C=O); 1712 (β-lactam); 1302 (Sec. Amine); 754 (C-Cl); <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 9.4 (-NH-); 8.4 (-OH); 7.0 to 8.0 (Ar-H); 6.8 (β lactam).

**Biological activity*****In vitro* α-amylase inhibitory activity:**

All the newly synthesized N-[3-Chloro-2-(Substituted)-4-oxazetidin-1-yl]-4-(1H-indole-3-yl) butanamide derivatives were evaluated for their α-amylase inhibitory activity and the percentage of inhibition for all the concentrations ranging from 50 μg/ml to 800 μg/ml was calculated. The percentage of inhibition of the standard acarbose was also calculated and it was found to be 91.58 % at the concentration 800 μg/ml comparing with control.

Among the newly synthesized compounds AZ<sub>3</sub> showed high α-amylase inhibitory activity at 50 μg/ml to 800 μg/ml concentration comparable with standard drug acarbose. AZ<sub>5</sub> and AZ<sub>2</sub> showed moderate α-amylase inhibitory activity at all the five concentrations ranging from 50 μg/ml to 800 μg/ml.

*In vitro* α-amylase inhibitory activity (% inhibition) of the compounds was given in **table 2**.

**Table 2: *In vitro* α-amylase inhibitory activity (% inhibition)**

| Compound          | 50μg/ml    | 100μg/ml   | 200μg/ml   | 400μg/ml   | 800μg/ml   |
|-------------------|------------|------------|------------|------------|------------|
| AZ1               | 9.18±0.64  | 14.40±0.43 | 24.50±0.76 | 30.51±0.64 | 41.86±0.60 |
| AZ2               | 29.65±0.65 | 42.29±0.64 | 51.61±0.54 | 58.56±0.75 | 70.57±0.31 |
| AZ3               | 38.24±0.56 | 48.66±0.65 | 59.48±0.72 | 71.09±0.59 | 89.49±0.70 |
| AZ4               | 12.59±0.55 | 24.20±0.56 | 33.41±0.47 | 41.66±0.40 | 50.35±0.61 |
| AZ5               | 22.83±0.89 | 33.05±1.03 | 44.62±0.46 | 51.76±0.53 | 61.97±1.12 |
| Standard Acarbose | 40.73±1.39 | 49.34±1.04 | 63.48±0.91 | 72.56±1.22 | 91.58±1.89 |

% inhibition values are given as mean ±SEM of three parallel measurements

**CONCLUSION**

In the present study, new N-[3-Chloro-2-(Substituted)-4-oxazetidin-1-yl]-4-(1H-indol-3-yl) butanamide derivatives were synthesized and evaluated for *in vitro* α-amylase inhibitory activity. This class of compounds is having promising α-amylase

inhibitory activity and effectively utilized as lead molecules for drug development. Further studies on this class of compounds are in progress for getting more information on pharmacological importance.

**BIBLIOGRAPHY:**

- Bhat IK, Sunil KC, Satyanarayana D and Kalluraya. (2007). The synthesis and antimicrobial study of some azetidinone derivatives with the *p*-anisidine moiety. *Journal of Serbian Chemical Society*, 72 (5) 437–442.
- Govindarajan R and Bhat A.R (2002) Synthesis of pyrazinoyl and related heterocycles as possible antitubercular agents *Indian Journal of Heterocyclic Chemistry*, 11, 337-338.
- Holla BS, Prasanna CS, Poojary B, Rao KS and Bhat UG. (2004). Synthesis and insecticidal activity of some 1, 3, 4-oxadiazoles derived from 2-chloropyridine-5-acetic acid *Indian Journal of Chemistry*, 43, 864-868.
- Keri RS, Hosamani KM, Reddy HS and Shingalapuri RV (2010). Synthesis, *in-vitro* antimicrobial and cytotoxic studies of novel azetidinone derivatives. *Archiv der Pharmazie* 343(4), 237-247.
- Mehta PD, Sengar NP and Pathak AK (2010). 2-Azetidinone-a new profile of various pharmacological activities. *European Journal of Medicinal Chemistry*. 45 (12):5541-60.
- Mohan TP, Vishalakshi B, Bhat KS, Rao, KS and Kendappa GN (2004). Synthesis and insecticidal activity of some 1,3,4-oxadiazole derivatives containing phenoxyfluorophenyl group. *Indian Journal of Chemistry*. *Indian Journal of Chemistry*, 43, 1798-1801.
- Udupi RH, Purushottamachar P and Bhat AR. (2000). Studies on antitubercular agents: Synthesis of 4-pyridoyl-3-substituted-1, 2, 4-triazolo (3, 4-b)(1, 3, 4)-thiadiazolidines. *Indian Journal of Heterocyclic Chemistry*, 9 (4), 287-290.
- Volgel HG. (2003). *Drug Discovery and Evaluation; Pharmacological Assay*, 2<sup>nd</sup> edition, Springer-Verlag, 1043.